Earnings summaries and quarterly performance for Carlyle Group.
Executive leadership at Carlyle Group.
Harvey M. Schwartz
Detailed
Chief Executive Officer
CEO
JN
Jeff Nedelman
Detailed
Co-President
JW
Jeffrey W. Ferguson
Detailed
General Counsel
JC
John C. Redett
Detailed
Chief Financial Officer and Head of Corporate Strategy
JP
Justin Plouffe
Detailed
Chief Financial Officer
LP
Lindsay P. LoBue
Detailed
Chief Operating Officer
MJ
Mark Jenkins
Detailed
Co-President
Board of directors at Carlyle Group.
AB
Afsaneh Beschloss
Detailed
Director
AW
Anthony Welters
Detailed
Director
DM
David M. Rubenstein
Detailed
Co-Chairman of the Board
DW
Derica W. Rice
Detailed
Director
JH
James H. Hance, Jr.
Detailed
Director
LW
Lawton W. Fitt
Detailed
Director
LH
Linda H. Filler
Detailed
Director
MS
Mark S. Ordan
Detailed
Lead Independent Director
SC
Sharda Cherwoo
Detailed
Director
WE
William E. Conway, Jr.
Detailed
Co-Chairman of the Board
WJ
William J. Shaw
Detailed
Director
Research analysts who have asked questions during Carlyle Group earnings calls.
Alexander Blostein
Goldman Sachs
5 questions for CG
Also covers: AB, AMG, AMP +31 more
Brian Bedell
Deutsche Bank
5 questions for CG
Also covers: AMG, AMTD, APO +23 more
BM
Brian McKenna
Citizens JMP Securities
5 questions for CG
Also covers: ARCC, ARES, BX +14 more
KW
Kenneth Worthington
JPMorgan Chase & Co.
5 questions for CG
Also covers: APO, ARES, BAM +27 more
Michael Cyprys
Morgan Stanley
5 questions for CG
Also covers: AAMI, AMP, AMTD +30 more
Patrick Davitt
Autonomous Research
5 questions for CG
Also covers: ABL, AMG, APO +10 more
WK
William Katz
TD Cowen
5 questions for CG
Also covers: AB, AMG, AMTD +25 more
GS
Glenn Schorr
Evercore ISI
4 questions for CG
Also covers: APO, BAC, BEN +14 more
Kyle Voigt
Keefe, Bruyette & Woods
4 questions for CG
Also covers: AMTD, APO, ARES +17 more
Benjamin Budish
Barclays PLC
3 questions for CG
Also covers: AB, APO, ARES +24 more
DF
Daniel Fannon
Jefferies Financial Group Inc.
3 questions for CG
Also covers: AB, AMG, AMTD +27 more
MB
Michael Brown
Wells Fargo Securities
3 questions for CG
Also covers: APO, ARES, BAM +19 more
SC
Steven Chubak
Wolfe Research
3 questions for CG
Also covers: AMP, AMTD, APO +20 more
Ben Budish
Barclays PLC
2 questions for CG
Also covers: AB, APO, ARES +22 more
Brendan O'Brien
Wolfe Research
1 question for CG
Also covers: EVR, HLI, LAZ +4 more
BH
Brennan Hawken
UBS Group AG
1 question for CG
Also covers: AMP, AMTD, APO +28 more
Craig Siegenthaler
Bank of America
1 question for CG
Also covers: AB, AMP, AMTD +26 more
Recent press releases and 8-K filings for CG.
Carlyle Sells Arctic Glacier
CG
M&A
New Projects/Investments
- Reddy Ice, LLC announced an agreement to acquire Arctic Glacier, LLC from Carlyle (NASDAQ: CG).
- The acquisition, for which terms were not disclosed, is subject to customary closing conditions including regulatory approvals.
- To address the DOJ Antitrust Division's review, Reddy Ice will divest four facilities and associated customer contracts in Washington, Idaho, and California, along with customer contracts in Oregon and in the New York and Boston metropolitan areas.
- The strategic rationale for the acquisition is to create increased operational efficiency and combine geographically complementary platforms across North America.
5 days ago
Centerra Gold's Mount Milligan Mine receives permit amendments for extended operations
CG
New Projects/Investments
Guidance Update
- Centerra Gold Inc.'s Mount Milligan Mine has received an amended environmental assessment and all related permits, allowing for the continuation of its operations through 2035.
- These authorizations include a 10% expansion in plant throughput beginning in 2028 and increased stockpile capacity.
- The Mount Milligan Mine was selected by the Province of British Columbia in January 2025 for expedited permitting.
- Centerra is also progressing studies to support a further mine life extension for Mount Milligan to 2045, as outlined in a Pre-Feasibility Study published on September 11, 2025.
Jan 21, 2026, 2:30 AM
Carlyle-backed Aspen Power Secures $200 Million Capital Commitment
CG
New Projects/Investments
Debt Issuance
- Aspen Power, a distributed generation platform backed by Carlyle, has secured a $200 million strategic capital commitment from Deutsche Bank.
- This financing is intended to accelerate Aspen Power’s development of distributed solar and storage projects nationwide, enhancing its financial capacity and supporting growth initiatives.
- Carlyle, as an existing backer, welcomes Deutsche Bank as a partner, noting this commitment strengthens Aspen Power's ability to deliver projects and supports its expansion.
Jan 12, 2026, 1:06 PM
Carson Group Unveils Bullish Market Outlook for 2026
CG
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Carson Group's Market Outlook 2026, titled "Riding the Wave," forecasts continued economic expansion and robust market performance.
- The outlook is driven by expansive fiscal policy, a decisive shift to monetary easing, and unprecedented investment in AI.
- Carson Group predicts the S&P 500 will gain between 12-15% in 2026.
- Key tailwinds include retroactive tax cuts, continued Federal Reserve rate cuts, easing tariff pressures, and strong global economic activity.
- AI-related capital expenditures are at historic highs, expected to reach $515 billion in 2026 from major technology firms, fueling economic growth and corporate profits.
Jan 8, 2026, 2:00 PM
Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights
CG
Earnings
Product Launch
New Projects/Investments
- Conavi Medical reported total revenue of $9.1 million for fiscal year 2025, a significant increase from $2.2 million in the prior year, and a net loss of $20.5 million or $0.36 per common share.
- The company submitted its next-generation Novasight Hybrid™ system to the U.S. FDA for 510(k) clearance in September 2025, advancing its U.S. commercialization plans.
- Conavi strengthened its financial position in fiscal 2025 with $20 million in gross proceeds from a public equity financing in April 2025 and ended the year with $5.8 million in cash and cash equivalents as of September 30, 2025.
- Ki Investments Europe S.à r.l. acquired beneficial ownership of approximately 28.34% of Conavi's common shares on a non-diluted basis from its affiliate Carlyle Services Limited Liability Company, effective December 24, 2025.
Dec 29, 2025, 12:38 PM
Carlyle CFO Transitions to Global Head of Private Equity Amid Strong Performance and Optimistic Outlook
CG
CFO Change
Guidance Update
New Projects/Investments
- Carlyle (CG) CFO, John Redett, is transitioning to Global Head of Private Equity, marking his last event in the CFO capacity.
- The company reported a strong year with record FRE over the last 12 months and $60 billion of inflows over the last six months, with the stock being a top performer in its space.
- Management is optimistic about 2026, anticipating a healthy deal environment with attractive rates, open financing markets, and accelerating M&A, leading to a busy year for new investments and monetizations.
- Carlyle revised its 2025 fundraising guidance to $50 billion and expects meaningful management fee growth over the next couple of years due to large funds coming to market.
- The wealth channel saw doubled inflows this year, and the recently launched private equity product (CPEP) is expected to accelerate meaningfully in 2026 and 2027.
Dec 9, 2025, 4:20 PM
Carlyle Discusses Strong Performance, Strategic Growth, and Leadership Transition
CG
CFO Change
Guidance Update
Revenue Acceleration/Inflection
- John Redett is transitioning from his role as CFO and Head of Corporate Strategy to Global Head of Private Equity.
- Carlyle is experiencing a strong year, with record FRE and approximately $60 billion of inflows over the last six months. The company anticipates a very healthy deal environment in 2026, with accelerating M&A and monetization.
- The firm has significant fundraising momentum, revising its 2025 guidance to $50 billion in inflows and expects meaningful management fee growth in 2026 and 2027 due to large funds coming to market.
- Carlyle is making substantial progress in its wealth channel, doubling inflows in 2025, and sees significant growth potential in its Asset-Backed Finance business, which has grown to $10 billion.
- The company aims for an FRE margin target of 40%-50%, currently at 48% in 2025, and is committed to shrinking its share count through share repurchases, having bought back $500 million year-to-date.
Dec 9, 2025, 4:20 PM
Carlyle CFO John Redett Transitions to Global Head of Private Equity Amid Strong Performance and Growth Outlook
CG
CFO Change
Guidance Update
Share Buyback
- John Redett, current CFO and Head of Corporate Strategy at Carlyle, is transitioning to Global Head of Private Equity, marking his last event as CFO.
- Carlyle reported a strong year with record FRE over the last 12 months and approximately $60 billion in inflows over the last six months. The company is on track to achieve $50 billion in inflows for the year, having raised $45 billion year to date through Q3.
- The firm anticipates significant fundraising opportunities in the next 18 months, with major flagship products like CP9 (U.S. buyout), CCOF (opportunistic credit), Infrastructure, Secondaries, Co-investment, and CLO business entering the market.
- Monetizations reached $32 billion across the firm through Q3, representing a 30%-35% increase, with Q4 net realized performance revenues expected to be multiples of Q3.
- Carlyle's FRE margin is approximately 48%, at the upper end of its 40%-50% target, with expectations for meaningful expansion through growth and scale, projecting 10%-11% FRE growth for the year. The company has repurchased $500 million in shares year to date and is focused on reducing its share count.
Dec 9, 2025, 4:20 PM
Carlyle Group-backed Adicon to Acquire Crown Bioscience
CG
M&A
New Projects/Investments
- JSR Life Sciences has entered a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited, a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group.
- The transaction is expected to close in 2026.
- This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership, positioning it to accelerate advancements in precision medicine and drug discovery for oncology.
- Crown Bioscience's Global Biospecimens business will remain fully integrated within JSR Life Sciences.
Nov 13, 2025, 8:45 AM
Carlyle Group Reports Q3 Earnings and Record AUM
CG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- The Carlyle Group reported a significant drop in third-quarter net income to $900,000 from nearly $596 million the previous year, with distributable earnings per share of 96 cents, missing analyst estimates.
- Despite the earnings miss, the firm achieved a record $474 billion in assets under management (AUM), driven by $17 billion in quarterly inflows and 11% fee revenue growth.
- Management raised full-year financial targets, expecting 10% fee-related earnings growth and $50 billion in inflows.
- The company's fee-related earnings margins stood at 48% for the quarter and year-to-date, surpassing last year's record of 46%.
Oct 31, 2025, 6:05 PM
Quarterly earnings call transcripts for Carlyle Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more